cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biomarin Pharmaceutical Inc
48 own
25 watching
Current Price
$90.02
$1.48
(1.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
18,568.63M
52-Week High
52-Week High
105.69000
52-Week Low
52-Week Low
76.02000
Average Volume
Average Volume
1.63M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
965.9684
iconMarket Capitalization18,568.63M
icon52-Week High105.69000
icon52-Week Low76.02000
iconAverage Volume1.63M
iconDividend Yield--
iconP/E Ratio965.9684
What does the Biomarin Pharmaceutical Inc do?
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Read More
How much money does Biomarin Pharmaceutical Inc make?
News & Events about Biomarin Pharmaceutical Inc.
TipRanks Financial Blog
8 months ago
In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN Research R... In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN &#8211...
Zolmax
9 months ago
BioMarin Pharmaceutical (NASDAQ:BMRN Get Rating) had its price objective decreased by Guggenheim from $125.00 to $120.00 in a report published on Thursday morning, The Fly reports. Other equities research analysts have also recently issued reports about the stock. Oppenheimer cut shares of BioMarin ...
Ticker Report
10 months ago
AIA Group Ltd lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) by 168.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,313 shares of the biotechnology companys stock after ...
Zolmax
10 months ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN Get Rating) CEO Jean Jacques Bienaime sold 10,000 shares of the companys stock in a transaction dated Thursday, April 6th. The stock was sold at an average price of $96.13, for a total transaction of $961,300.00. Following the completion of the transaction, ...
PR Newswire
11 months ago
BioMarin Provides Update on FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A BioMarin Provides Update on FDA Review of ROCTAVIAN (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A PR Newswire SAN RAFAEL, Calif., March...
Frequently Asked Questions
Frequently Asked Questions
What is Biomarin Pharmaceutical Inc share price today?
plus_minus_icon
Can Indians buy Biomarin Pharmaceutical Inc shares?
plus_minus_icon
How can I buy Biomarin Pharmaceutical Inc shares from India?
plus_minus_icon
Can Fractional shares of Biomarin Pharmaceutical Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biomarin Pharmaceutical Inc stocks?
plus_minus_icon
What is today’s traded volume of Biomarin Pharmaceutical Inc?
plus_minus_icon
What is today’s market capitalisation of Biomarin Pharmaceutical Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biomarin Pharmaceutical Inc?
plus_minus_icon
What percentage is Biomarin Pharmaceutical Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biomarin Pharmaceutical Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$90.02
$1.48
(1.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00